Modality
Gene Editing
MOA
C5i
Target
PD-L1
Pathway
Autophagy
RAFTD
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
Mar 2017
→ Apr 2029
Phase 2Current
NCT06804451
2,733 pts·FTD
2022-11→2026-12·Recruiting
NCT05032589
61 pts·FTD
2017-03→2029-04·Active
2,794 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-068mo awayPh3 Readout· FTD
2029-04-263.1y awayPh3 Readout· FTD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-12-06 · 8mo away
FTD
Ph3 Readout
2029-04-26 · 3.1y away
FTD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06804451 | Phase 2/3 | FTD | Recruiting | 2733 | DOR |
| NCT05032589 | Phase 2/3 | FTD | Active | 61 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| MRU-8112 | Merus | Preclinical | PD-L1 |